Antares Pharma doses first rheumatoid arthritis patient in VIBEX MTX clinical trial
The study will evaluate several dose strengths of VIBEX MTX which is being developed for the treatment of rheumatoid arthritis. VIBEX MTX is Antares’ proprietary – wholly owned
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.